D&P Bioinnovations

D&P Bioinnovations is a regenerative medicine company focused on developing bioresorbable scaffolds to repair and regenerate damaged organs, with an initial focus on the esophagus. Their lead product is a patent-pending implant designed to treat conditions such as esophageal atresia and esophageal cancer by facilitating the regeneration of the patient's own tissue. The company's technology aims to replace the current standard of care, which often involves complex and risky surgeries like gastric pull-ups or intestinal interpositions. By utilizing a combination of advanced materials and regenerative biology, D&P Bioinnovations seeks to provide a less invasive and more effective solution for gastrointestinal repair. The company is currently progressing through pre-clinical development and has received significant support from the NIH and NSF. Their esophageal implant has been granted Orphan Drug and Rare Pediatric Disease designations by the FDA, highlighting the significant unmet need in this space.